Literature DB >> 28528849

Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability.

Senthilvelrajan Kaniyappan1, Ram Reddy Chandupatla2, Eva-Maria Mandelkow3, Eckhard Mandelkow4.   

Abstract

INTRODUCTION: Tau-mediated toxicity in Alzheimer's disease is thought to operate through low-n oligomers, rather than filamentous aggregates. However, the nature of oligomers and pathways of toxicity are poorly understood. Therefore, we investigated structural and functional aspects of highly purified oligomers of a pro-aggregant tau species.
METHODS: Purified oligomers of the tau repeat domain were characterized by biophysical and structural methods. Functional aspects were investigated by cellular assays ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay of cell viability, lactate dehydrogenase release assay [for cell toxicity], reactive oxygen species production, and calcium assay), combined with analysis of neuronal dendritic spines exposed to oligomers.
RESULTS: Purified low-n oligomers are roughly globular, with sizes around 1.6 to 5.4 nm, exhibit an altered conformation, but do not have substantial β-structure. Treatment of primary neurons with oligomers impairs spine morphology and density, accompanied by increased reactive oxygen species and intracellular calcium, but without affecting cell viability (by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay of cell viability and lactate dehydrogenase release assay [for cell toxicity]). DISCUSSION: Tau oligomers are toxic to synapses but not lethal to cells.
Copyright © 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calcium elevation; Neurons; Oligomers; ROS production; Structure; Synapses; Tau; Toxicity; Transgenic mouse brain-derived oligomers

Mesh:

Substances:

Year:  2017        PMID: 28528849     DOI: 10.1016/j.jalz.2017.04.002

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  29 in total

Review 1.  The structure and phase of tau: from monomer to amyloid filament.

Authors:  Yifan Zeng; Jing Yang; Bailing Zhang; Meng Gao; Zhengding Su; Yongqi Huang
Journal:  Cell Mol Life Sci       Date:  2020-10-19       Impact factor: 9.261

2.  The role of wild-type tau in Alzheimer's disease and related tauopathies.

Authors:  Chih Hung Lo; Jonathan N Sachs
Journal:  J Life Sci (Westlake Village)       Date:  2020-12

3.  Mitochondrial oxidative stress contributes to the pathological aggregation and accumulation of tau oligomers in Alzheimer's disease.

Authors:  Fang Du; Qing Yu; Nicholas M Kanaan; Shirley ShiDu Yan
Journal:  Hum Mol Genet       Date:  2022-08-17       Impact factor: 5.121

4.  Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.

Authors:  Varun Balaji; Senthilvelrajan Kaniyappan; Eckhard Mandelkow; Yipeng Wang; Eva-Maria Mandelkow
Journal:  Autophagy       Date:  2018-09-13       Impact factor: 16.016

5.  Phosphorylation of Tau protein correlates with changes in hippocampal theta oscillations and reduces hippocampal excitability in Alzheimer's model.

Authors:  Siddhartha Mondragón-Rodríguez; Anahí Salas-Gallardo; Perla González-Pereyra; Martín Macías; Benito Ordaz; Fernando Peña-Ortega; Azucena Aguilar-Vázquez; Erika Orta-Salazar; Sofía Díaz-Cintra; George Perry; Sylvain Williams
Journal:  J Biol Chem       Date:  2018-04-09       Impact factor: 5.157

Review 6.  Super-resolution microscopy: a closer look at synaptic dysfunction in Alzheimer disease.

Authors:  Pranesh Padmanabhan; Andrew Kneynsberg; Jürgen Götz
Journal:  Nat Rev Neurosci       Date:  2021-11-01       Impact factor: 34.870

Review 7.  The Role of Post-Translational Modifications on the Structure and Function of Tau Protein.

Authors:  Haiqiong Ye; Yue Han; Ping Li; Zhengding Su; Yongqi Huang
Journal:  J Mol Neurosci       Date:  2022-03-24       Impact factor: 2.866

8.  Letter.

Authors:  Ara S Khachaturian
Journal:  Alzheimers Dement (Amst)       Date:  2017-11-21

9.  Inhibition of Tau aggregation with BSc3094 reduces Tau and decreases cognitive deficits in rTg4510 mice.

Authors:  Marta Anglada-Huguet; Sara Rodrigues; Katja Hochgräfe; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  Alzheimers Dement (N Y)       Date:  2021-06-01

10.  Synaptic Loss in Primary Tauopathies Revealed by [11 C]UCB-J Positron Emission Tomography.

Authors:  Negin Holland; P Simon Jones; George Savulich; Julie K Wiggins; Young T Hong; Tim D Fryer; Roido Manavaki; Selena Milicevic Sephton; Istvan Boros; Maura Malpetti; Frank H Hezemans; Franklin I Aigbirhio; Jonathan P Coles; John O'Brien; James B Rowe
Journal:  Mov Disord       Date:  2020-07-11       Impact factor: 9.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.